Pure Global: Malaysia's Home-Use Devices & The Digital Dilemma of E-Labelling

This week on ASEAN MedTech Insights, we dive into a major regulatory update from Malaysia. The Medical Device Authority (MDA) has just greenlit e-labelling for home-use medical devices, a move that promises to cut costs and modernize market access. This shift allows companies to replace bulky paper manuals with digital instructions for use (e-IFU). While this sounds like a straightforward win for efficiency, it introduces a complex new challenge known as the "digital dilemma". Manufacturers must now conduct rigorous risk assessments to prove patients can reliably access and use these digital instructions. For a company making a state-of-the-art wearable health monitor for seniors, this creates a critical pain point: how do they prove their target demographic, who may not be tech-savvy, can access the e-IFU without issue, a crucial step they might have overlooked in their rush to adopt the new standard. Key Questions (本期干货): 1. What are the new e-labelling rules from Malaysia's Medical Device Authority? 2. Which types of home-use medical devices are most affected by this change? 3. Why is a risk assessment the most critical step before switching to e-labelling? 4. What happens if a patient can't access the electronic instructions? What are the manufacturer's obligations? 5. How can you prove to regulators that your digital instructions are always available and user-friendly? 6. Could this e-labelling move be a double-edged sword for MedTech companies? 7. How does this policy reflect broader digital health trends across ASEAN? At Pure Global, we specialize in navigating these complex regulatory landscapes. Our end-to-end solutions, combining local expertise with advanced AI tools, help MedTech and IVD companies streamline global market access and ensure full compliance. To turn regulatory hurdles into market opportunities, contact us at [email protected] or visit us at https://pureglobal.com/.